← Back to Search

Abatacept with Oral Immunotherapy for Peanut Allergy (ATARI Trial)

Phase 2
Waitlist Available
Research Sponsored by Philippe Bégin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female subjects 14 to 50 years old at screening visit
Be younger than 65 years old
Must not have
Current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants or beta-blocker
Uncontrolled asthma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 2, 6, 12, 36 and 48

Summary

This trial will test if the drug abatacept can help people with severe peanut allergies achieve remission.

Who is the study for?
This trial is for 14 to 50-year-olds with a severe, persistent peanut allergy confirmed by specific tests. Participants must be willing to follow the study's rules but can't join if they've had bad reactions to abatacept, are at risk of infections like HIV, have uncontrolled asthma or heart issues, use certain medications like steroids or antidepressants, are pregnant/breastfeeding, or have other chronic diseases that could interfere.
What is being tested?
The trial is testing whether adding Abatacept to peanut oral immunotherapy helps adolescents and adults with severe peanut allergies reach remission. It's a phase 2a study where half the participants get Abatacept and the other half get a placebo for six months while undergoing immunotherapy.
What are the potential side effects?
Possible side effects of Abatacept may include increased risk of infections due to immune system suppression, infusion-related reactions such as discomfort or pain at injection site, headache, nausea and potential allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 14 and 50 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently using steroids, tricyclic antidepressants, or beta-blockers.
Select...
My asthma is not well-managed.
Select...
I have been diagnosed with an eosinophilic gastrointestinal disorder.
Select...
I am at risk of sepsis due to a weakened immune system or HIV.
Select...
I am currently being treated with a biological therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 2, 6, 12, 36 and 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 6, 12, 36 and 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Peanut specific/total IgE at week 24
Secondary study objectives
Adverse events
Desensitization
Desensitization speed
+4 more
Other study objectives
Atopy patch test
Peanut specific/total IgE, other time points
Peanut-specific IgG4, other time points
+2 more

Side effects data

From 2017 Phase 2 trial • 37 Patients • NCT00932828
78%
Rash (not hives)
62%
Nausea/vomiting
59%
Abdominal pain
54%
Hives
51%
Skin/oral pruritus
35%
Sneezing/congestion
30%
Multiple symptoms
100%
80%
60%
40%
20%
0%
Study treatment Arm
Peanut Oral Immunotherapy

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AbataceptExperimental Treatment2 Interventions
Group II: PlaceboPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abatacept
2005
Completed Phase 4
~112250

Find a Location

Who is running the clinical trial?

Philippe BéginLead Sponsor
2 Previous Clinical Trials
588 Total Patients Enrolled
Centre hospitalier de l'Université de Montréal (CHUM)OTHER
377 Previous Clinical Trials
131,366 Total Patients Enrolled

Media Library

Peanut Allergy Research Study Groups: Abatacept, Placebo
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top